Nilotinib Stada (Nilotinib)

Nilotinib is a targeted therapy used within the chronic myeloid leukemia treatment pathway.

• Chronic phase CML: improves survival and reduces disease progression when used as first‑line therapy.
• Accelerated phase CML: provides disease control for patients who have progressed beyond chronic phase.
• Blast phase CML: used in combination with other agents to achieve remission in advanced disease.

• Nilotinib selectively inhibits the BCR‑ABL tyrosine kinase, blocking its ATP‑binding site and preventing downstream signaling that drives proliferation of leukemic cells. By halting this pathway, the drug reduces abnormal cell growth and induces apoptosis of malignant clones, restoring normal hematopoiesis.

Nilotinib may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: loose stools, often transient.
• Rash: skin erythema or pruritus.
• Headache: mild to moderate intensity.
• Fatigue: generalized tiredness.
• Myalgia: muscle aches.

Serious or Rare Side Effects

• QT prolongation: risk of cardiac arrhythmia.
• Pancreatitis: severe abdominal pain with elevated enzymes.
• Hepatic injury: marked elevation of liver transaminases.
• Severe neutropenia: increased infection risk.
• Severe thrombocytopenia: bleeding tendency.
• Anaphylactic reactions: rare but potentially life‑threatening.

Before initiating therapy, clinicians should assess several safety parameters.

• Cardiac monitoring: obtain baseline ECG and repeat periodically to detect QT prolongation.
• Hepatic function: check liver enzymes before and during treatment.
• Pancreatic enzymes: monitor amylase and lipase levels regularly.
• Hematologic surveillance: perform complete blood counts to detect neutropenia or thrombocytopenia.
• Drug interactions: avoid concomitant strong CYP3A4 inhibitors and QT‑prolonging agents.
• Pregnancy: contraindicated; classified as Category D, advise effective contraception.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Nilotinib interacts with several medicines that can alter its plasma concentration or cardiac safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase nilotinib exposure and toxicity.
• QT‑prolonging agents (e.g., amiodarone, sotalol): additive risk of arrhythmia.
• Antacids containing aluminum or magnesium: reduce nilotinib absorption.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): may modestly raise levels.
• CYP3A4 inducers (e.g., St. John’s wort, rifampin): may lower efficacy.
• Warfarin: monitor INR as nilotinib can affect anticoagulation control.